<DOC>
	<DOCNO>NCT01165190</DOCNO>
	<brief_summary>Mitochondrial dysfunction skeletal muscle result decrease muscle fatty acid oxidation , lead conversion fatty acid triglyceride accumulation inside muscle tissue . Moreover , adipose tissue mitochondrial dysfunction result decrease fatty acid oxidation triglyceride synthesis , lead increase circulate fatty acid concentration , turn also lead lipid accumulation inside muscle tissue . Lipid accumulation inside muscle tissue interfere insulin signal pathway cause insulin resistance . Mitochondrial dysfunction tissue therefore propose play important role insulin resistance human . Pioglitazone , thiazolidinedione , FDA approve medication treatment type 2 diabetes . It improve muscle insulin sensitivity least part lower intramuscular lipid concentration mechanism occur unclear . In present study , shall therefore test hypothesis pioglitazone improve mitochondrial function muscle adipose tissue human insulin resistant .</brief_summary>
	<brief_title>Effect Pioglitazone Mitochondrial Function Muscle Adipose Tissue Humans</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>1 . Subjects must able communicate meaningfully investigator must legally competent provide write informed consent . 2 . Subjects may either sex age describe protocol . Female subject must nonlactating eligible negative pregnancy test throughout study period . 3 . Subjects must range age 1865 . 4 . Subjects must follow laboratory value : 2hour OGTT plasma glucose 140250 mg/dl Hematocrit ≥ 35 vol % Serum creatinine ≤ 1.6 mg/dl AST ( SGOT ) &lt; 2.5 time upper limit normal ALT ( SGPT ) &lt; 2.5 time upper limit normal PT , PTT within normal range 1 . Subjects must receive medication know effect glucose tolerance unless subject stable dose agent past three month entry study . Subjects take systemic glucocorticoid exclude . Subjects may take stable dose estrogens hormonal replacement therapy , subject agent prior three month . 2 . History clinically significant heart disease , include ischemic heart disease ( New York Heart Classification great grade II ; nonspecific STT wave change EKG ) congestive heart failure 3 . History peripheral vascular disease ( history claudication ) 4 . History pulmonary disease ( dyspnea exertion one flight le ; abnormal breath sound auscultation ) . 5 . History peripheral edema 6 . Uncontrolled hypertension systolic BP &gt; 160 mmHg , diastolic BP &gt; 100 mmHg 7 . Resting heart rate &gt; 100 beats/min 8 . Autonomic neuropathy 9 . Heavy alcohol consumption ( &gt; 2 drinks/day )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>